AA
GYRE icon

AlphaCentric Advisors’s Gyre Therapeutics GYRE Stock Holding History

AlphaCentric Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,200
Closed -$469K – 244
2021
Q3 		$469K Sell
15,200
-9,133
-38% -$301K 0.12% 72
2021
Q2 		$790K Buy
24,333
+16,333
+204% +$561K 0.21% 38
2021
Q1 		$302K Buy
+8,000
New +$366K 0.1% 74

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AlphaCentric Advisors's GYRE Position: Q4 2021 in Review

AlphaCentric Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 15,200 shares — an estimated $469K sold.

AlphaCentric Advisors first reported a position in GYRE in Q1 2021 and held it in 3 quarters. The position peaked at $790K in Q2 2021. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • AlphaCentric Advisors reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 15,200 Gyre Therapeutics shares in Q4 2021, an estimated $469K.
  • AlphaCentric Advisors first reported a position in Gyre Therapeutics in Q1 2021 and held it in 3 quarters.
  • AlphaCentric Advisors's Gyre Therapeutics position peaked at $790K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.